Ruchat David, Suter Marc R, Rodondi Pierre-Yves, Berna Chantal
Faculté de Biologie et Médecine, Université de Lausanne UNIL, 1015 Lausanne.
Centre d'antalgie, Service d'anesthésiologie, CHUV, 1011 Lausanne.
Rev Med Suisse. 2018 Jun 20;14(612):1262-1266.
In North America the massive increase in opioid prescriptions for chronic non-cancer pain has been a major health issue for several years. In Switzerland, the situation is less well known. This article aims to present the evolution of the Swiss consumption and replace it in a European and international context using the International Narcotics Control Board database. Between 1985 and 2015, the Swiss opioid consumption raised from 18 to 421 mg/person/year, making Switzerland the 7th largest opioid consumer per capita in the world. This increase could be due to more adequate pain management or liberalized opioid prescription for indications unsupported by the current evidence. Given these elements, further research is needed, yet increased caution is recommended when prescribing opioid drugs.
在北美,用于慢性非癌性疼痛的阿片类药物处方量大幅增加多年来一直是一个主要的健康问题。在瑞士,情况鲜为人知。本文旨在介绍瑞士阿片类药物消费的演变情况,并利用国际麻醉品管制局数据库将其置于欧洲和国际背景下进行分析。1985年至2015年间,瑞士人均阿片类药物消费量从每年18毫克增至421毫克,使瑞士成为世界上人均阿片类药物消费量第七高的国家。这种增长可能是由于疼痛管理更加得当,或者是针对目前证据不足的适应症放宽了阿片类药物处方。鉴于这些因素,需要进一步研究,但在开具阿片类药物处方时建议更加谨慎。